Clinical TrialA dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model-Science-Chemical Encyclopedia-lookchem

Clinical TrialA dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model
Add time:08/29/2019 Source:sciencedirect.com

SummaryObjectivesPain and disability are the main clinical manifestations of osteoarthritis, for which only symptomatic therapies are available. Hence, there is a need for therapies that can simultaneously alter disease progression and provide pain relief. KBP is a dual amylin- and calcitonin-receptor agonist with antiresorptive and chondroprotective properties. In this study we investigated the effect of KBP in a rat model of osteoarthritis.

We also recommend Trading Suppliers and Manufacturers of AMYLIN (8-37) (RAT) (cas 138398-61-5). Pls Click Website Link as below: cas 138398-61-5 suppliers

Prev:Original articleThe protective effect of Azadirachta excelsa leaves extract and quercetin treatment on the learning and memory impairments in relation with insulin and amylin levels in the brain of streptozotocin-induced diabetic rats
Next: BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats)

Click to view details

Encyclopedia